Concurrent low-volume HIIT plus resistance training improves cardiometabolic markers in overweight adults

A randomized controlled trial published online Feb. 23, 2026 compared concurrent, low‑volume high‑intensity interval training (HIIT) paired with resistance training (RT) against alternative training modalities and nutritional guidance in overweight adults, and measured cardiometabolic markers and interindividual variability. The Feb. 23 trial excerpt supplied here does not include sample size, numeric outcomes, or the exact HIIT/RT prescription, so the study’s detailed effect sizes remain to be reviewed.

Context from recent trials shows consistent but study-specific benefits when aerobic and resistance components are combined. In a 20‑week randomized trial of 26 women with severe or morbid obesity, participants were assigned to HIIT+RT (n = 14; mean age 45.79, 95% CI 40.74-50.83) or RT+HIIT (n = 12; mean age 33.6, 95% CI 25.30-41.79). The Pmc Ncbi report states that “the RT+HIIT group showed significant reductions in WC (∆ –3.84 cm, p = 0.015), SBP (∆ –8.46 mmHg, p = 0.040), whereas the HIIT+RT group elicited significant reductions only in SBP (∆ –8.43 mmHg, p = 0.022).” That same report notes the HIIT+RT configuration “promoted a lower prevalence of NRs than the RT+HIIT configuration on WC,” while overall RT+HIIT produced slightly more beneficial training‑induced effects on markers of metabolic syndrome.

A 12‑week trial in adults and older adults with metabolic syndrome compared RT+HIIT and RT+MICT and found broader cardiometabolic gains but also important null results. As the Frontiersin authors write, “The findings of the present study suggest that both modes of concurrent training (i.e. RT+HIIT and RT+MICT) provide multiple cardiometabolic benefits in adults and older adults with MetS after a 12-week intervention.” That paper also reports that “both exercise interventions did not change high sensitivity C-reactive protein, glycated hemoglobin, high density lipoprotein and total cholesterol, systolic, diastolic or mean arterial blood pressure (P ≥ 0.05). The CON group reduced the LDL (P = 0.031).” The Frontiersin team flags “small-to-moderate effect size and the short-term intervention length” and calls for longer trials.

A 12‑week randomized trial in adults with type 2 diabetes mellitus found modality-specific advantages: combined aerobic–resistance training and HIIT both improved metabolic, functional, and quality‑of‑life outcomes versus standard care, with HIIT “superior for fasting glucose reduction and muscle mass gains, whereas A + R produced greater improvements in HbA1c, adiposity reduction, and multiple domains of quality of life,” according to the PLoS‑style excerpt.

Program design and dose matter. A Springer summary of a five‑month hybrid program in inactive, overweight women reported weekly exercise volume of approximately 100 minutes, net exercise time per session of 6.5–24.0 minutes, session durations of 23–41 minutes at 73–87% maximum heart rate and RPE 14–16, and concluded the combined exercise “provided a significant improvement in cardiorespiratory fitness” and “reduced LDL and triglyceride levels significantly compared to the control group.” That source also links HIIT to mechanistic effects such as increased myocardial VEGF and capillary density.

Across these studies authors explicitly discuss interindividual variability and sequence effects. Trial excerpts and protocol literature raise nonresponders (NRs) as a measurable phenomenon and urge that “order session” and intensity be treated as components of precision exercise prescriptions. Given differing populations, durations (12 weeks to 5 months), and reported outcomes, the direct clinical takeaway is cautious: concurrent low‑volume HIIT plus resistance training shows promise for improving cardiometabolic markers across overweight, obese, MetS, and T2DM populations, but effect sizes, responder rates, and optimal sequencing vary by study and require larger, longer, and fully reported trials before broad changes to programming. Verify the full Feb. 23, 2026 manuscript for sample size, protocol details, and complete numeric results before translating this specific trial into programming decisions.